Inhibrx Biosciences, Inc. (INBX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$161.7M
Cash & Equivalents
$38.0M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$1,365M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-30 | Phase2 Readout | — |
| 2027-04-14 | Pdufa | — |
| 2027-06-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06295731 | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | PHASE3 | Active Not Recruiting | 410 |
| NCT04950075 | Study of INBRX-109 in Conventional Chondrosarcoma | PHASE2 | Active Not Recruiting | 206 |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Met... | PHASE2 | Active Not Recruiting | 296 |
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | PHASE2 | Recruiting | 12 |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | PHASE1 | Recruiting | 411 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-15 | 8-K | Inhibrx Biosciences, Inc. (INBX) (CIK 0002007919) - EX-99.1 | EDGAR |